392-04-1

Basic information

• Product Name: METHYL 4-FLUORO-2-HYDROXYBENZOATE
• Synonyms: Methyl 4-fl;4-Fluoro-2-hydroxybenzoic acid methyl ester;Methyl 4-fluorosalicylate, 5-Fluoro-2-(methoxycarbonyl)phenol;METHYL 4-FLUORO-2-HYDROXYBENZOATE;METHYL 4-FLUOROSALICYLATE;RARECHEM AL BF 1428;4-Fluorosalicylic acid methyl ester~Methyl 4-fluoro-2-hydroxybenzoate;Methyl4-fluorosalicylate~Methyl2-hydroxy-4-fluorobenzoate
• CAS NO: 392-04-1
• Molecular Formula: C₈H₇FO₃
• Molecular Weight: 170.14
• EINECS: -0
• Product Categories: Benzoic acid;Acids & Esters;Fluorine Compounds;Phenols
• Mol File: 392-04-1.mol
• Article Data: 22

Chemical Properties

• Melting Point: 38-40°C
• Boiling Point: 225℃
• Flash Point: 90℃
• Appearance: /
• Density: 1.309
• Vapor Pressure: 0.0603mmHg at 25°C
• Refractive Index: 1.526
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 8.76±0.10(Predicted)
• BRN: 2087920
• CAS DataBase Reference: METHYL 4-FLUORO-2-HYDROXYBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 4-FLUORO-2-HYDROXYBENZOATE(392-04-1)
• EPA Substance Registry System: METHYL 4-FLUORO-2-HYDROXYBENZOATE(392-04-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• Hazardous Substances Data: 392-04-1(Hazardous Substances Data)

Usage

Uses

Methyl 4-Fluoro-2-hydroxybenzoate is a useful synthetic intermediate. It was used to prepare benzo[d]isoxazol-3-ol as D-amino acid oxidase inhibitors. It is also used in the discovery of hydroxy-indazole-carboxamides as inhibitors of Hsp90.

InChI:InChI=1/C8H7FO3/c1-12-8(11)6-3-2-5(9)4-7(6)10/h2-4,10H,1H3

Upstream product

• 67-56-1 methanol 
• 345-29-9 4-fluorosalicylic acid 
• 403-33-8 methyl 4-flurobenzoate 
• 1583-58-0 2,4-difluoro-benzoic acid 
• 74-88-4 methyl iodide 
• 455-68-5 methyl 3-fluorobenzoate 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 870837-58-4 4-(1H-imidazol-1-yl)-2-methoxybenzoic acid methyl ester 
• 204707-42-6 methyl 4-fluoro-2-methoxybenzoate 
• 501378-87-6 methyl 2-((dimethylcarbamothioyl)oxy)-4-fluorobenzoate 
• 644970-09-2 methyl 4-fluoro-2-[(2S)-oxiran-2-ylmethoxy]benzoate 
• 753922-57-5 methyl 2-(benzyloxy)-4-fluorobenzoate 
• 1056954-60-9 4-fluoro-2-hydroxybenzohydrazide 
• 1380495-48-6 4-fluoro-2-(2-methoxyethoxy)-1-(2-methoxyvinyl)benzene 
• 1380495-49-7 [4-fluoro-2-(2-methoxyethoxy)phenyl]acetaldehyde 
• 1380495-50-0 2-[4-fluoro-2-(2-methoxyethoxy)phenyl]ethanol 
• 1380495-69-1 2-(1-{2-[4-fluoro-2-(2-methoxyethoxy)phenyl]ethyl}-piperidin-4-yl)-N-[(1R)-1-(4-fluorophenyl)-2-methylpropyl]-acetamide hydrochloride 
• 959641-51-1 4-fluoro-2-(2-methoxyethoxy)benzaldehyde 
• 1380495-51-1 2-[4-fluoro-2-(2-methoxyethoxy)phenyl]ethyl 4-methylbenzenesulfonate 
• 1380495-47-5 [4-fluoro-2-(2-methoxyethoxy)phenyl]methanol 
• 1380495-46-4 methyl 4-fluoro-2-(2-methoxyethoxy)benzoate 

Relevant articles and documents

Discovery of highly potent SARS-CoV-2 Mpro inhibitors based on benzoisothiazolone scaffold

The COVID-19 pandemic has drastically impacted global economies and public health. Although vaccine development has been successful, it was not sufficient against more infectious mutant strains including the Delta variant indicating a need for alternative treatment strategies such as small molecular compound development. In this work, a series of SARS-CoV-2 main protease (Mpro) inhibitors were designed and tested based on the active compound from high-throughput diverse compound library screens. The most efficacious compound (16b-3) displayed potent SARS-CoV-2 Mpro inhibition with an IC50 value of 116 nM and selectivity against SARS-CoV-2 Mpro when compared to PLpro and RdRp. This new class of compounds could be used as potential leads for further optimization in anti COVID-19 drug discovery.

BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING

A compound of formula (I); wherein: W is O or NH; A1 1 is CRAA or N; A22 is CRBB or N; A3A3 is CRCC or N; A44 is CRDD or N; where no more than two of A11, A

ASK1 INHIBITING AGENTS

Provided are compounds of Formulas (I'), (I), (II') and (II), or pharmaceutically acceptable salts thereof, and methods for their use and production.